|Bid||43.47 x 900|
|Ask||43.85 x 800|
|Day's Range||42.71 - 44.03|
|52 Week Range||9.64 - 84.49|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.00|
LA JOLLA, Calif., Jun 16, 2021--DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today three new key leadership appointments: Loren Clarke, M.D. to the role of Chief Medical Officer, Ray Bassi to the role of Vice President, Sales and Patrick Johnson to the role of Vice President, Information Technology and Digital Systems.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, DermTech...
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced an investor update presentation will be available at 9:00 a.m. ET on Monday, June 7 at http://www.humacyte.com/investor_update. The presentation will review the Company’s clinical programs and progress, as well as its scientific platform and current business plans. The presentation will b